Compare Northrop Grumman Corporation (NOC) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs Organon & Co. Common Stock — how do they compare? Northrop Grumman Corporation trades at $496.19 (market cap $68.39B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Northrop Grumman Corporation is far larger — about 18.9× Organon & Co. Common Stock's market cap, and Northrop Grumman Corporation pays the higher dividend (2.05%). Which is the better fit depends on your goals — on Pluang, investors hold Northrop Grumman Corporation for 82 Days and Organon & Co. Common Stock for 0 Days on average.
| NOC | OGN | |
|---|---|---|
Market Cap | $68.39B | $3.62B |
Volume | 823,323 | 2,892,999 |
Sector | Industrials | Health |
52-Week High | $768.02 | $13.81 |
52-Week Low | $473.46 | $5.70 |
Typical Hold Time | 82 Days | 0 Days |
Enterprise Value | $82.37B | $11.04B |
Dividend Yield | 2.05% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $495.69, up 2.2% on the day, amid a bearish technical signal but strong fundamentals. The company has beaten earnings estimates for the last three quarters, with a net income margin of 10.48% and a P/E ratio of 15.3. Recent news highlights a $20 billion Navy fighter contract loss to Boeing, though the company maintains a record backlog and a dividend payout.
The outlook is mixed: analyst consensus is bullish with a $595.69 price target, but technical indicators and recent contract loss pose near-term risks. Long-term growth is supported by defense spending and key programs like the B-21 bomber, though competitive pressures and execution risks remain.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
